WO2002098399A3 - Cancer treatment method and compositions comprising compounds of the ginger family - Google Patents

Cancer treatment method and compositions comprising compounds of the ginger family Download PDF

Info

Publication number
WO2002098399A3
WO2002098399A3 PCT/US2002/017705 US0217705W WO02098399A3 WO 2002098399 A3 WO2002098399 A3 WO 2002098399A3 US 0217705 W US0217705 W US 0217705W WO 02098399 A3 WO02098399 A3 WO 02098399A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
treatment method
cancer treatment
ginger family
Prior art date
Application number
PCT/US2002/017705
Other languages
French (fr)
Other versions
WO2002098399A2 (en
Inventor
Zigang Dong
Ann M Bode
Wei-Ya Ma
Original Assignee
Univ Minnesota
Zigang Dong
Ann M Bode
Wei-Ya Ma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Zigang Dong, Ann M Bode, Wei-Ya Ma filed Critical Univ Minnesota
Priority to EP02734677A priority Critical patent/EP1392266A2/en
Priority to AU2002305823A priority patent/AU2002305823A1/en
Priority to US10/479,899 priority patent/US20040156799A1/en
Priority to CA002449450A priority patent/CA2449450A1/en
Publication of WO2002098399A2 publication Critical patent/WO2002098399A2/en
Publication of WO2002098399A3 publication Critical patent/WO2002098399A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides pharmaceutical compositions including: a combination of a compound of the formula (I) wherein R1 is C1-C6 alkyl and R2 is independently -H or -OH, or a pharmaceutically acceptable salt thereof; and a phorbol compound. The present invention also provides for these and other compositions and their use for the treatment of established cancers or tumors.
PCT/US2002/017705 2001-06-05 2002-06-04 Cancer treatment method and compositions comprising compounds of the ginger family WO2002098399A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02734677A EP1392266A2 (en) 2001-06-05 2002-06-04 Cancer treatment method and compositions comprising compounds of the ginger family
AU2002305823A AU2002305823A1 (en) 2001-06-05 2002-06-04 Cancer treatment method and compositions comprising compounds of the ginger family
US10/479,899 US20040156799A1 (en) 2002-06-04 2002-06-04 Cancer treatment method and compositions
CA002449450A CA2449450A1 (en) 2001-06-05 2002-06-04 Cancer treatment method and compositions comprising compounds of the ginger family

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29609801P 2001-06-05 2001-06-05
US60/296,098 2001-06-05

Publications (2)

Publication Number Publication Date
WO2002098399A2 WO2002098399A2 (en) 2002-12-12
WO2002098399A3 true WO2002098399A3 (en) 2003-02-27

Family

ID=23140595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017705 WO2002098399A2 (en) 2001-06-05 2002-06-04 Cancer treatment method and compositions comprising compounds of the ginger family

Country Status (4)

Country Link
EP (1) EP1392266A2 (en)
AU (1) AU2002305823A1 (en)
CA (1) CA2449450A1 (en)
WO (1) WO2002098399A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2411229C2 (en) * 2004-09-23 2011-02-10 Учреждение Российской академии наук Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН (ТИБОХ ДВО РАН) Therapeutic quinones
US20080181877A1 (en) * 2006-03-22 2008-07-31 Leangene Ab, C/O Cit Ekonomiservice Ab Method For Monitoring the Effect of Compounds on Foxc2 Expression
FR2950884B1 (en) * 2009-10-01 2011-11-11 Oreal USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, METHOD OF PRESERVATION, COMPOUNDS AND COMPOSITION
CN103222986A (en) * 2012-01-31 2013-07-31 岳旺 Application of gingerol and ruddle composition in preparation of attenuated synergistic medicaments in cancer chemotherapy
KR101547735B1 (en) 2013-12-09 2015-08-26 가천대학교 산학협력단 Composition for treating or preventing brain damage comprising Paradol
WO2017097362A1 (en) * 2015-12-10 2017-06-15 Symrise Ag Composition with stabilized taste and odor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARK KWANG-KYUN ET AL: "Inhibitory effects of (6)-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice.", CANCER LETTERS, vol. 129, no. 2, 17 July 1998 (1998-07-17), pages 139 - 144, XP001119376, ISSN: 0304-3835 *
SURH Y-J: "MOLECULAR MECHANISMS OF CHEMOPREVENTIVE EFFECT OF SELECTED DIETARY AND MEDICINAL PHENOLIC SUBSTANCES", MUTATION RESEARCH, AMSTERDAM, NL, vol. 428, 1999, pages 305 - 327, XP000905254, ISSN: 0027-5107 *
SURH YOUNG-JOON ET AL: "Anti-tumor-promoting activities of selected pungent phenolic substances present in ginger.", JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, vol. 18, no. 2, 1999, pages 131 - 139, XP009000260, ISSN: 0731-8898 *

Also Published As

Publication number Publication date
CA2449450A1 (en) 2002-12-12
WO2002098399A2 (en) 2002-12-12
AU2002305823A1 (en) 2002-12-16
EP1392266A2 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
YU23202A (en) Drugs for the treatment of malignant tumors
SE0002320D0 (en) Malignant tumors
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
MXPA04004674A (en) Cannabinoid receptor ligands.
PL367682A1 (en) Dolastatin 10 derivatives
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
GB0112348D0 (en) Compounds
EP1714961A4 (en) Indazole compound and pharmaceutical use thereof
WO2003041660A3 (en) Solubilized topoisomerase poisons
EE200000472A (en) Antineoplastic agents
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
ATE390923T1 (en) TOPOISOMERASE TOXICANTS
WO2003051289A3 (en) Solubilized topoisomerase poison agents
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family
EP1253139A3 (en) Multioligoanilinated fullerenes
WO2004044174A3 (en) Topoisomerase-targeting agents
WO2007001839A3 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2004035002A3 (en) Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
AU2002359762A1 (en) Luminacin analogs and uses thereof
AU4485101A (en) Antiviral therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2449450

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10479899

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002734677

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002734677

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP